ImageneBio (IMA) Q1 2026 earnings summary

Executive summary

• Completed a reverse merger and divestiture in July 2025, resulting in a single clinical-stage asset, IMG-007, focused on immunological, autoimmune, and inflammatory diseases.

• Raised $75M in PIPE financing in 2025 and $30M in April 2026 through a private placement of pre-funded warrants, extending the cash runway into Q1 2028.

• IMG-007, a non-T cell-depleting OX40 antagonist, is in a Phase 2b trial for atopic dermatitis (AD) with topline data expected in Q4 2027; a Phase 2 study in alopecia areata (AA) is planned for late 2026.

• Preclinical data on IMG-007 will be presented at the SID Meeting in May 2026, highlighting its differentiated mechanism and safety profile.

Financial highlights

• Net loss for Q1 2026 was $10.6M, compared to $6.1M or $9.1M in Q1 2025, driven by increased R&D and G&A expenses.

• Cash, cash equivalents, and marketable securities totaled $117.2M as of March 31, 2026.

• Research and development expenses rose to $6.0M (from $4.0M), and general and administrative expenses increased to $6.1M (from $2.8M) year-over-year.

• No revenue recognized in Q1 2026 following the divestiture of non-OX40 programs.

Outlook and guidance

• Cash runway, including April 2026 financing, is expected to support operations into Q1 2028 and key clinical milestones.

• Substantial additional funding will be required to advance IMG-007 through clinical development and potential commercialization.

• Topline Phase 2b AD data expected in Q4 2027; initial AA Phase 2 data anticipated in 2028.